Werewolf Therapeutics
1030 Massachusetts Avenue
Cambridge, MA 02138
United States
Tel: 617-952-0555
Email: jobs@werewolftx.com
About Werewolf Therapeutics
Werewolf Therapeutics, Inc. is an oncology biotherapeutics company unleashing the power of proinflammatory immune modulators to develop next-generation, transformative cancer therapeutics. The company is advancing a pipeline of treatments designed to focus the body’s immune response to selectively target cancer.
Under precise conditions, Werewolf’s technology allows it to zero in on tumors using validated mechanisms that are known cancer killers, while preventing unwanted side effects on non-target tissues – ultimately delivering a more clinically meaningful impact for patients.
Werewolf’s proprietary PREDATOR™ protein engineering platform combines a variety of approaches to actively silence the drug while in systemic circulation, optimize its pharmacokinetic profile, and rapidly and efficiently transform into the fully active state upon reaching the tumor microenvironment for maximum therapeutic potential.
Werewolf is creating a new era of tumor-selective, systemically delivered drugs with the potential to deliver more effective, less toxic treatments for people with cancer, with the goal of vastly improving their lives.
12 articles with Werewolf Therapeutics
-
Werewolf Therapeutics Appoints Chulani Karunatilake, Ph.D. as Chief Technology Officer
6/15/2021
Werewolf Therapeutics, Inc., an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to stimulate the body’s immune system for the treatment of cancer, announced the appointment of Chulani Karunatilake, Ph.D. as Chief Technology Officer.
-
Werewolf Therapeutics Reports First Quarter 2021 Financial Results
6/10/2021
Werewolf Therapeutics, Inc. announced financial results for the quarter ended March 31, 2021.
-
Werewolf Therapeutics Appoints Mike Sherman to its Board of DirectorsOver 30 years of experience in advancing therapeutics to commercial launch and driving companies to successful operations and strategic transactions
5/28/2021
Werewolf Therapeutics, Inc., an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to stimulate the body’s immune system for the treatment of cancer, announced the appointment of Mike Sherman, chief executive officer of Chimerix, Inc., as a member of its board of directors.
-
Werewolf Therapeutics to Present at Jefferies Virtual Healthcare Conference 2021
5/27/2021
Werewolf Therapeutics, Inc. (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to stimulate the body’s immune system for the treatment of cancer, today announced that Daniel J. Hicklin, Ph.D., President and Chief Executive Officer of Werewolf Therapeutics, will present at Jefferies Virtual Healthcare Conference on Thursday, June 3rd, at 11 am ET.
-
After quietly filing plans for an initial public offering earlier this month, U.K.-based Vaccitech raised $110.5 million in its IPO.
-
Werewolf Therapeutics Announces Pricing of Upsized Initial Public Offering
4/29/2021
Werewolf Therapeutics, Inc. (NASDAQ: HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to stimulate the body’s immune system for the treatment of cancer, today announced the pricing of its upsized initial public offering of 7,500,000 shares of common stock at a public offering price of $16.00 per share
-
BioSpace Movers & Shakers, Feb. 12
2/12/2021
Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers. -
Werewolf Therapeutics Appoints Tim Trost as Chief Financial Officer
2/8/2021
Werewolf Therapeutics appoints Veteran life sciences financial executive brings over 25 years finance and capital markets expertise
-
Werewolf Therapeutics Completes $72 Million Series B Financing to Advance a Novel Class of Cancer Biotherapeutics to the Clinic
1/7/2021
Financing accelerates Werewolf's pipeline of systemically delivered, conditionally activated INDUKINE™ molecules into clinical stage development and supports efforts to build a leading immuno-oncology drug discovery and development team
-
This week multiple companies have announced millions of investment dollars have flooded their coffers to advance research and development of multiple therapies. BioSpace is rounding up the announcements.
-
BioSpace is proud to present its NextGen Bio “Class of 2021,” a list of up-and-coming life sciences companies in North America that recently launched.
-
Werewolf Therapeutics Appoints Dr. Randi Isaacs as Chief Medical Officer
11/9/2020
Expansion of leadership team with deep translational oncology drug development expertise as Company prepares for clinical development of lead programs